2015年于中山大学获医学博士学位

后留中山医学院工作

主持多项国家、省、市级科研项目 主要科研项目

国家自然科学基金（青年基金），间质干细胞对CD23+CD43+调节性B细胞的调控作用及机制研究、81600102、2017.01-2019.12、项目负责人。 广东省科技计划项目（公益研究与能力建设），调节性B细胞在间质干细胞治疗炎症性肠病中的作用及机制研究、2016A020214003、2016.01-2018.12、项目负责人。 广州市珠江科技新星专项，B淋巴细胞亚群在间质干细胞治疗慢性移植物抗宿主病中的作用机制研究、201906010095、2019.04-2021.03、项目负责人。 国家重点研发计划，不同来源间充质干细胞防治异基因造血干细胞移植后移植物抗宿主病的临床优化方案及机理研究、2017YFA0105500、2017.07-2021.12、课题骨干。 [标签:头像]

以第一作者发表学术论文/论著7篇，包括Leukemia, Theranostics, Mol Ther, Cell Mol Immunol.等 主要学术论文：

Chen X#, Cai C#, Xu D#, Liu Q, Zheng S, Liu L, Li G, Zhang X, Li X, Ma Y, Huang L, Chen J, Shi J, Du X, Xia W*, Xiang AP*, Peng Y*. Human mesenchymal stem cell-treated regulatory CD23+CD43+ B cells alleviate intestinal inflammation. Theranostics. 2019; 9(16): 4633-4647. (IF 8.063) Wang H#, Li D#, Zhai Z#, Zhang X, Huang W, Chen X, Huang L, Liu H, Sun J, Zou Z, Fan Y, Ke Q, Lai X, Wang T, Li X, Shen H, Xiang AP*, Li W*. Characterization and Therapeutic Application of Mesenchymal Stem Cells with Neuromesodermal Origin from Human Pluripotent Stem Cells. Theranostics. 2019;9(6):1683-1697. (IF 8.063) Chen X#, Liu Q#, Xiang AP*. CD8+CD28- T cells: not only age-related cells but a subset of regulatory T cells. Cell Mol Immunol. 2018;15(8):734-736. (IF 8.213) Chen X#, Liu Q#, Huang W#, Cai C, Xia W, Peng Y, Zheng S, Li G, Xu Y, Wang J, Liu C, Zhang X, Huang L, Xiang AP*, Zhang Q*. Stanniocalcin-2 Contributes to Mesenchymal Stromal Cells Attenuating Murine Contact Hypersensitivity mainly via reducing CD8+ Tc1 Cells. Cell Death Dis. 2018; 9(5): 548. (IF 5.959) Lin BL#, Chen JF#, Qiu WH, Wang KW, Xie DY, Chen XY, Liu QL, Peng L, Li JG, Mei YY, Weng WZ, Peng YW, Cao HJ, Xie JQ, Xie SB, Xiang AP*, Gao ZL*. Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: A randomized controlled trial. Hepatology. 2017;66(1):209-219. (IF 14.971) Zhang X#, Huang W#, Chen X#, Lian Y, Wang J, Cai C, Huang L, Wang T, Ren J*, Xiang AP*. CXCR5-overexpressing Mesenchymal Stromal Cells Exhibit Enhanced Homing and Can Decrease Contact Hypersensitivity. Mol ther. 2017, 7;25(6):1434-1447. (IF 8.402) Qin A#, Lai DH#, Liu Q#, Huang W#, Wu YP, Chen X, Yan S, Xia H, Hide G, Lun ZR*, Ayala FJ*, Xiang AP*. Guanylate-binding protein 1 (GBP1) contributes to the immunity of human mesenchymal stromal cells against Toxoplasma gondii. Proc Natl Acad Sci U S A. 2017;114(6):1365-1370. (IF 9.58) Chao K#, Zhang S#, Qiu Y#, Chen X, Zhang X, Cai C, Peng Y, Mao R, Pevsner-Fischer M, Ben-Horin S, Elinav E, Zeng Z, Chen B, He Y, Xiang AP*, Chen M*. Human umbilical cord-derived mesenchymal stem cells protect against experimental colitis via CD5(+) B regulatory cells. Stem Cell Res Ther. 2016;7(1):109. (IF 4.627) Peng Y#, Chen X#, Liu Q#, Zhang X, Huang K, Liu L, Li H, Zhou M, Huang F, Fan Z, Sun J, Liu Q, Ke M, Li X, Zhang Q, Xiang AP*. Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5+ regulatory B cells producing interleukin 10. Leukemia. 2015,29(3):636-46.(IF 9.944) Liu Q#, Zheng H#, Chen X#, Peng Y, Huang W, Li X, Li G, Xia W, Sun Q*, Xiang AP*. Human mesenchymal stromal cells enhance the immunomodulatory function of CD8+CD28- regulatory T cells. Cell Mol Immunol. 2015;12(6):708-18. (IF 8.213) Peng Y#, Chen X#, Liu Q#, Xu D, Zheng H, Liu L, Liu Q, Liu M, Fan Z, Sun J, Li X, Zou R, Xiang AP*. Alteration of Naive and Memory B-Cell Subset in Chronic Graft-Versus-Host Disease Patients After Treatment With Mesenchymal Stromal Cells. Stem Cells Transl Med. 2014,3(9):1023-31. (IF 5.962)